This is the authors' abstract. We don't add key points for this paper.
Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Saad et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: